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Autosomal dominant polycystic kidney disease (ADPKD) is a devastating multi-organ disease lacking a cure. 
ADPKD accounts for approximately 5–10% of patients with renal failure. Genetically, it arises predominately due 
to mutations in the Pkd1 or Pkd2 genes, encoding for the polycystin-1 and polycystin-2 proteins. he disease is 
characterised by the progressive growth and enlargement of renal cysts. Patients with ADPKD also exhibit a vas-
cular phenotype, presenting with hypertension and aneurysms1,2 which together with cysts in kidneys and other 
organs, shows that ADPKD is a systemic disease. Currently Tolvaptan, a V2-vasopressin receptor antagonist, 
is the only approved therapy; however, it carries signiicant side efects3 and in is available to some, but not all, 
patients with ADPKD. herefore, a major biomedical challenge is to identify central druggable pathways for the 
treatment of ADPKD.
Curcumin (diferuloylmethane)4 is a phytochemical known to exhibit strong JAK/STAT inhibitory activity. 
Consistent with being a JAK/STAT inhibitor,  curcumin exhibits robust antioxidant, anti-tumour and 
anti-inlammatory efects5. Importantly, no appreciable side-efects have been reported making it an attractive 
drug for long-term inhibition of this pathway. Because of its low toxicity but potency, curcumin has been tested as 
a therapeutic in ADPKD murine models, where it limites cystic growth6 and is currently being trialled in young 
patients and children with ADPKD (clinicaltrials.gov - NCT02494141).
We have recently shown that JAK2/STAT5 activity is abnormally activated and contrib-
utes to ADPKD7–11. Others have also shown that additional components of the JAK/STAT path-
way are dysregulated in ADPKD, previously reviewed11. The mechanisms underlying JAK/STAT 
hyperactivity in ADPKD are however unknown. STAT transcription factors become activated by a 
series of phosphorylation events on conserved tyrosine residues facilitated by one of four JAK kinases, 
namely JAK1-JAK3 or Tyk2. Because of their involvement in disease, JAK small-molecule inhibitors 
have been developed, including the approved Tofacitinib, Ruxolitinib, and Baracitinib12–15. Moreover, 
additional JAK inhibitors are in clinical trials, making JAK-STAT a therapeutically tractable pathway. 
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Evidence exists that STAT1, STAT3, STAT5 and STAT6 are involved in ADPKD pathogenesis (7–9,11,16–23), 
while on the contrary the involvement of JAK kinases, which are druggable, has not been previously studied in 
ADPKD. Combining our previous and current work with that of other groups we predict that JAK-STAT inhi-
bition may be of therapeutic beneit in ADPKD. We therefore investigated the expression of JAK2 in kidneys of 
mice with and without ADPKD and inhibited JAK2 activity to examine its role in cystogenesis.

 ?in vivoǤ To investigate 
whether JAK2 is involved in the development of cysts in vivo, we stained kidney sections from the Pkd1nl/nl mouse 
model24 and associated wild-type littermate controls with anti-JAK2 antibodies. Kidneys from 5 weeks old mice, 
with intermediate disease, and 10 weeks old with advance disease, were studied as previously described7. We 
found that JAK2 is difusely expressed by cortical renal epithelial cells and its expression appears predominately 
cytoplasmic with no detectable expression by ibroblasts or the interstitium (Fig. 1A and A’). During early stages 
of ADPKD, JAK2 is strongly expressed by renal cystic tubules, and to a lesser extent by non-cystic, otherwise 
Figure 1. JAK2 is highly expressed by cystic renal epithelial cells in vivo. JAK2 levels were studied in kidneys 
sections of the Pkd1nl/nl model at 5 and 10 weeks of age (5 mice in each group), representative images at 20x 
magniication are shown. Kidneys of Pkd1 wild type littermates exhibit JAK2 staining through the kidney 
parenchyma with strong expression in tubules (A). 5 weeks of age Pkd1nl/nl mice exhibit JAK2 expression in 
both cystic and non-cystic tubules (c, denotes cysts) (B). While at 10 weeks of age the cysts of the Pkd1nl/nl are 
larger and JAK2 is highly expressed in epithelial (C and C’) but also ectopically expressed in the interstitium 
(i). Expression of JAK2 is also found in vessels (v). JAK2 quantiication revealed stronger expression in cystic 
epithelial when compared with non-cystic and with wild-type normal tubules (D).
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normal, tubular epithelial cells (Fig. 1B). At 10 weeks of age, as the disease advances evident by increased num-
ber of larger cysts and difuse interstitial expansion, JAK2 is strongly expressed in cystic epithelial cells and this 
expression appears to be stronger in cystic than in healthy non-cystic tubules. Quantiication of JAK2 staining 
intensity indicated that mice with intermediate and late stages of disease (5 and 10 weeks) have stronger JAK2 
in cystic when compared to non-cystic tubules and compared to wild-type littermate animals (Fig. 1D). Some 
JAK2 expression is detected in interstitial cells in mice with ADPKD (Fig. 1C’) which is absent in healthy kidneys 
(Fig. 1A’), suggesting that JAK2 expression in the interstitium is ectopic. JAK2 is expressed in vessels with a lesser 
expression by bowman’s capsule cells (Fig. 1C’). Expression of JAK2 in vessels remains strong as disease pro-
gresses (Fig. 1C). Hence, JAK2 expression is temporally and spatially coincident with cyst growth in the Pkd1nl/nl 
mouse model of ADPKD.
 ?Ǥ Since JAK2 is highly 
expressed in cystic epithelial cells in vivo (Fig. 1) we considered whether blocking JAK2 activity may ofer pro-
tection against cystogenesis and set out to explore this biochemically in vitro. Studies in non-renal systems, with 
intact Pkd1-triggered signalling, have suggested that curcumin acts as a strong JAK-STAT inhibitor25–27, an obser-
vation conirmed by our studies (Supplementry Fig. 1A). We used curcumin to inhibit JAK/STAT activity in three 
independent ADPKD-derived epithelial cell lines; three cell lines were used to avoid cell-line speciic artefacts. 
All ADPKD lines tested here did not show signs of constitutive activation of JAK/STAT, hence to activate the 
pathway, we used a deined amount of oncostatin M (OSM)28. 50µΜ of curcumin for 6 hours potently inhib-
ited the OSM-induced STAT3 activity, indicated by a marked reduction in the level of tyrosine phosphorylation 
Figure 2. Curcumin is a potent STAT3 inhibitor in renal ADPKD-derived epithelial cells. (A) Oncostatin 
M (OSM, 10 ng/ml) was used to stimulate phosphorylation of STAT3. Western blotting was performed with 
total cell lysates from human ADPKD-derived epithelial cells OX161-c1, SKI-001 and mouse F1 Pkd1−/−. 
Anti- STAT3 phospho-tyrosine 705 antibody (pY STAT3), total STAT3 (STAT3) and β-actin, which served as 
an internal loading control, were used. In all three cell lines curcumin treatment inhibited OSM-induced pY 
STAT3. (B) SKI001 cells treated with either 100, 50 or 25 µM of curcumin were subjected to blotting for STAT3, 
pYSTAT3 and β-actin control. Densitometric quantiication of three independent blots was carried out. One-
way Anova with Bonferroni corrections was performed, and values lower that 0.05 were considered statistically 
signiicant. (C) SKI001 cells were treated with 100 µM of curcumin for 1 or 3 or 6 hours and stimulated either 
with water vehicle control or 10 ng/ml of OSM. pYSTAT3, STAT3 and β-actin were investigated by blotting. 
Quantiication of three independent blots was carried out. One-way Anova with Bonferroni corrections was 
performed, and values lower that 0.05 were considered statistically signiicant. Symbol meaning: *P ≤ 0.05, 
**P ≤ 0.01, ***P ≤ 0.001, ****P ≤ 0.0001.
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(Fig. 2A), without afecting total STAT3 protein levels. We next performed a time-response curve, which showed 
that one-hour of curcumin treatment is suicient to cause nearly 50% reduction in STAT3 phosphorylation while 
3 and 6 hours result in 100% reduction. Total STAT3 protein levels were unaltered by the treatment (Fig. 2B). To 
study the amount of curcumin needed to cause 50% decrease in phosphorylation of STAT3, cells were stimulated 
for three hours with 100, 50 or 25 µM of curcumin. Treatment with 100 µM and 50 µM caused 100% reduction in 
tyrosine phosphorylation, while 25 µM only reduced it by 50%. hese time- and dose-dependent data show that 
curcumin potently blocks STAT3 activity in ADPKD-derived epithelial lines.
 ? ?Ǥ To ind out how curcumin blocks STAT3 activity we studied 
JAK2, which is highly expressed by cyst-lining cells in vivo (Fig. 1) and is known to activate STAT3 by phospho-
rylation. We found that 100 µM and 50 µM of curcumin caused approximately 100% reduction in JAK2 levels, 
while 25µΜ resulted in a modest 50% decrease (Fig. 3). Curcumin reduced JAK2 levels in both OSM-treated 
and control-treated cells, hence showing that it afects JAK2 in an OSM-independent manner. Curcumin’s efect 
on JAK2 activity was consistent with the blockade of STAT3 phosphorylation observed above (Fig. 2). To test if 
this efect was not cell line speciic, we tested the efect of curcumin in mouse F1-Pkd1−/− cells and found that 
curcumin reduced JAK2 levels (Supplementry Fig. 2B). herefore, curcumin blocks JAK2 and this may explain 
the reduced STAT3 activity.
 ? ?Ǥ We next wished to understand 
how curcumin causes the apparent alteration of the levels of JAK2 in immunoblots. Firstly, we explored the option 
that curcumin may cause JAK2 degradation via proteasomal processing of JAK2. To assess this, we treated cells 
with MG132, a proteasome inhibitor. MG132 caused the expected increase in ubiquitinated proteins, thus con-
irming adequate level of proteasomal blockade (Fig. 4A). Yet, the efect of curcumin on JAK2 did not depend on 
the proteosome, as MG132 was unable to restore JAK2 levels following curcumin treatment (Fig. 4A compare lane 
3 with 7 and 8). hese data show that curcumin-induced JAK2 reduction is not though the proteasome. Given that 
the proteasome is not responsible for the decreased JAK2 levels we decided to perform immunocytochemistry 
to visualise JAK2 and test whether curcumin treatment afects its subcellular localisation. Interestingly, we found 
that JAK2 is found throughout the cell body with some localisation in the plasma membrane in DMSO-vehicle 
treated cells, however curcumin treatment causes JAK2 to become strongly punctate (Fig. 4B). Previous studies 
have suggested that curcumin can cause protein precipitation into aggresomes29,30, we therefore suggest that these 
punctate structures may be JAK2 aggregates. his could explain how JAK2 becomes insoluble and provide an 
explanation as to why we were unable to detect JAK2 in the detergent-soluble fraction by immunoblotting. Taken 
together, our data show that curcumin causes JAK2 inactivation without involving the proteasome.
Ǧ ?in vitroǤ To study the ability of the JAK2/
STAT3 pathway to drive cystogenesis we performed cystogenesis assays in vitro using a monoculture grown in 
three dimensions (3D cyst assays). We used three independent cell lines to ensure the robustness of results and 
avoid cell-type speciic artefacts. In these assays microscopic cysts formed, from each independent cell line, which 
grew in diameter over time, as previously shown by our group7. We found that curcumin-induced JAK2 blockade 
led to a clear and reliable reduction in the size of cysts in all three independent cell lines tested and, in a time 
and dose-dependent manner (Fig. 5). Critically, two of the three cell lines used are human derived cells, there-
fore highlighting human relevance. Curcumin reduced the growth of cysts at day 2, with the efect persisting 
to day 6 and 9. Curcumin at 50 and 25µΜ also clearly reduced cyst size at day 9 in OX161-c1 cells, which are 
human-derived ADPKD cells (Fig. 5A). A similar pattern was seen in SKI-001, an additional independent human 
ADPKD-derived line, which showed reduced cyst size at day 6 and 9 with 50 and 25µΜ of curcumin (Fig. 5B). 
We also studied a mouse line which has a Pkd1 deletion and is therefore considered as a mouse ADPKD line, 
as expected curcumin blocked the growth of cysts at day 2 with 100 µM of curcumin, while day 6 and day 9 50 
Figure 3. Curcumin inhibits JAK2. SKI001 cells were exposed to 100 or 50 or 25 µM of curcumin and 
immunoblot was carried out using anti-JAK2 and β-actin antibodies. Total JAK2 is found in both OSM 
stimulated and unstimulated cells. Quantiication of three independent immunoblots was carried out. One-
way Anova with Bonferroni corrections was carried out and values lower that 0.05 were considered statistically 
signiicant. Symbol meaning: *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001, ****P ≤ 0.0001.
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and 100µΜ were able to cause a block in the growth of cysts (Fig. 5C). Pkd1 wild-type F1 mouse renal cells also 
responded by exhibiting reduced cystic growth (data not shown), suggesting that the strong anti-cystogenic efect 
of curcumin is Pkd1-independent. To study whether JAK/STAT in indeed activated in cells grown in 3D cyst 
Figure 4. Curcumin controls JAK2 localisation. (A) SKI001 cells were treated with OSM (10 ng/ml), or MG132 
(50 µM) or curcumin (50 µM) for 3 hours and lysates were subjected to immunoblotting. Antibodies against 
JAK2 pYSTAT3, STAT3, ubiquitin (indicator of proteasome inhibition control) and β-actin (internal loading 
control) were studied. (B) SKI001 cells were either treated with DMSO vehicle control for 3 hours (3 h) or 
curcumin for 1 h or 3 h or 6 h, they were then snap frozen on ice-cold methanol, stained with anti-JAK2 rabbit 
antibody, followed by an anti-rabbit AF594 and imaged in an inverted luorescent microscope. Red is anti-JAK2 
(also in greyscale in lower panel), blue is nuclear counterstain (DAPI). Scale bars are 25 µm.
6SCIENTIFIC REPORTS |          (2019) 9:4491  | ǣȀȀǤȀ ? ?Ǥ ? ? ? ?Ȁ ? ? ? ? ?Ǧ ? ? ?Ǧ ? ? ? ? ?Ǧ ?
www.nature.com/scientificreportswww.nature.com/scientificreports/
assay and investigate if curcumin is able to block STAT3 phosphorylation, we performed immunoblotting from 
cyst assays. STAT3 is phosphorylated within the cysts and curcumin potently blocks this (Fig. 5D), as well as 
reducing JAK2 levels (Supplementry Fig. 1C). hese data suggest that the previously reported anti-cystic actions 
Figure 5. Curcumin slows down cyst growth in vitro. ADPKD-derived human epithelial cells were grown 
in BD-Matrigel to allow the formation of cysts to grow over time. All cysts formed were photographed at day 
0, 2, 6 and 9; using an Olympus inverted microscope. Curcumin at 100, 50, 25 and 10 µM or DMSO vehicle-
control was added and cyst growth measured in (A) human OX161 (B) human SKI-001 and (C) mouse derived 
Pkd1−/− cell lines. (D) Immunoblots were performed from cell lysates obtained from cells grown in cysts at day 
9. Matrigel was melted and pYSTAT3 was measured, β-actin was also assessed. Cells were treated with either 0, 
50 or 100 µM of curcumin to test whether the latter can reduce JAK/STAT activity in the cysts. One-way Anova 
with Bonferroni corrections was carried out and values lower that 0.05 were considered statistically signiicant. 
Symbol meaning: *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001, ****P ≤ 0.0001.
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of curcumin may be via blockade of JAK/STAT. Given that curcumin is pleiotropic and can block pathways other 
than just JAK/STAT we also used a selective JAK small-molecule inhibitor, namely tofacitinib, which is cur-
rently in clinical use for rheumatoid arthritis. We found that tofacitinib led to a signiicant reduction in cyst size 
(Fig. 4E), thus suggesting that JAK inhibition alone is suicient to block cystic growth of ADPKD cells.

We show that JAK2 levels are higher in polycystic when compared with wild-type kidneys a inding that may 
be therapeutically relevant given that we identiied that JAK blockade, using either curcumin or a selective JAK 
inhibitor, potently reduces cystic growth in human ADPKD-derived lines. hese data are important because 
multiple components of the JAK/STAT pathway contribute to cystogenesis, and JAK activity is therapeutically 
amenable, therefore providing a realistic potential for intervention studies. Our data suggest that JAK2 is a key 
kinase promoting cystic growth in ADPKD, since inhibiting it, blocks cystic growth of ADPKD cells. JAK2 may 
contribute to the development of cystic growth likely via canonical activation of one, or multiple, of the down-
stream STAT transcription factors. Indeed, a number of groups, including our own, have shown that STAT3, 
STAT5 and STAT6, which are normally latent transcription factors, are activated in ADPKD7,10,11,18–21,23,31. JAK2 
is involved in tyrosine phosphorylation of all of these STATs32–34, which is an essential step for the dimeriza-
tion and activity of these transcription factors. herefore, the inhibition of cystic growth observed under JAK 
blockade may be via suppression of canonical JAK/STAT activity. Alternately, STAT transcription factors can 
also be activated, non-canonically, by other kinases such as Src, which was found to be responsible for activating 
STAT3 in MDCKII renal cells31. Indeed, curcumin can the biochemical activity of the Src kinase35 in addition 
to blocking JAK/STAT activity. If STATs are activated by Src or other kinases, then it follows that highlt selective 
small-molecule inhibitors of JAKs would not be efective in reducing JAK/STAT activity and lowering cystic 
growth. However, our work shows that tofacitinib, which is a selective JAK inhibitor, used at concentrations found 
in plasma of treated individuals, resulted in reduced cyst growth. herefore, we conclude that JAK2 is a major 
kinase driving cystogenesis of ADPKD cells.
he choice of JAK inhibitor is based on a number of considerations, including how efective a given drug is 
and balancing this with its side efects. Over the years, phytochemicals, such as curcumin, have been used to 
inhibit, prevent or reverse disease processes. Curcumin for example has strong anti-cystic efects in pre-clinical 
models of ADPKD6. One advantage of curcumin is that it can be used long term, due to lack of apparent side 
efects36. However, the bioavailability of curcumin is low37,38, making it less attractive when compared with small 
molecule inhibitors, such as tofacitinib, the JAK inhibitor used in our study. Indeed, here we showed that both 
curcumin and tofacitinib were capable of slowing down the rate of growth of cysts in cystogenesis assays. A 
comparison of tofacitinib (and other JAK inhibitors) with curcumin in a pre-clinical setting is required to assess 
efectiveness and measure their side efects in murine models of ADPKD.
Previous studies used systemic administration of curcumin in a murine model of ADPKD6, where curcumin 
showed promising results; however, whether curcumin acted primarily on renal epithelial or vascular cells was 
uncertain from these studies. Here, we ind that JAK2 is expressed in both vascular and epithelial cells in the 
ADPKD afected kidney. To gain a deeper understanding we used monoculture assays and found that curcumin 
reduces cystogenesis of renal epithelial cells without requiring interactions with vascular cells. As such, if, and 
how, curcumin afects vessels is currently unknown. However, curcumin is currently under clinical investigation 
(phase 4 clinical trial) for its potential to modify the vascular phenotype in children and young individuals with 
ADPKD. he results of this study may determine whether curcumin can protect the vasculature of young individ-
uals afected with against ADPKD, which will provide an additional protective mechanism for this drug.
Curcumin causes JAK2 to move into an insoluble fraction, and we observe the generation of large JAK2 pos-
itive puncta in cells treated with curcumin. We do not know the nature of these puncta, however, curcumin has 
been previously shown to cause protein aggregation29, therefore we propose that these structures may be aggre-
somes. he observation that these JAK2 positive puncta are not dependent on proteasomal processing of JAK2 
is evidence that JAK2 has not been degraded. Likewise, others have reported that curcumin-treated cancer cells 
respond by a temporal blockade of STAT3, which is fully reversible within 24 hours39, this is consistent with our 
observations. herefore, we propose a model whereby curcumin takes JAK2 briely out of action by causing it to 
aggregate, without leading to JAK2 degradation, which is an irreversible action. It should be noted that the efects 
of tofacitinib are also reversible but it requires up to 14 days for reversibility. his is important because it may 
explain the lack of signiicant side efects in response to systemic treatment with curcumin.
In summary, we show that JAK2 is highly expressed in polycystic kidneys and its blockade reduces cystic 
growth. Understanding how key signalling pathways, such as the JAK/STAT, are misregulated in ADPKD will 
help identify suitable molecules to target for therapy. Based on our in vivo immunohistochemical analysis an in 
vitro cyst assays in human cells, we propose that JAK inhibitors may be of therapeutic beneit for patients with 
ADPKD. More studies are required to explore the mechanisms employed by JAK-STAT to regulate cystic growth 
and to identify the most suitable point in the pathway to intervene. In conclusion, our study provides the basis for 
further testing of JAK inhibitors as a novel therapeutic avenue for patients with polycystic kidney disease.

Ǥ Conditionally-immortalized ADPKD-derived lines (OX161-c1 and SKI-001)40 are tubular epi-
thelial cells isolated from human kidneys and immortalized by transduction at an early passage (P1-4) with a 
retroviral vector containing a temperature-sensitive large T antigen and the catalytic subunit of human telomer-
ase41. he F1-Pkd1 WT renal epithelial cells were previously isolated from kidney papillae of the Pkd1l/l mouse 
(B6.129S4-Pkd1tm2Ggg/J; the Jackson Laboratory) and were immortalized with the lentiviral vector VVPW/
mTert expressing the mTert; to delete Pkd1 and produce F1/Pkd1−/− cells they were subsequently transfected 
with VIRHD/HY/Silntβ1/2363 lentivectors followed by hydromycin selection42.
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Ǥ Cyst assays were performed as previously described7. In brief, for ADPKD cystic cell lines, 2 
human lines namely OX161-c1, SKI-001, and one mouse line F1-Pkd1−/− were used. OX161 and SKI-001 were 
kept at 33 °C F1-Pkd1−/− were at 37 °C. Healthily growing cells were trypsinised and re-suspended in DMEM 
media containing 10% FBS (no antibiotics) and counted using a haemocytometer. Subsequently 2 × 104 cells per 
well were mixed with basement Matrigel (354230, BD biosciences). Prior to use, the Matrigel was let to thaw 
on ice and once cells were added it was immediately loaded onto the 96 well plate, allowing it to polymerise. 
100 µl of DMEM media supplemented with 10% FBS was added to each well and cells returned to the incubator 
for 24 hours to allow them to recover. Ater 24 hours, the media was aspirated and replaced with fresh media 
(DMEM + 10% FBS) supplemented with either vehicle (DMSO) or curcumin (Sigma). he cells were photo-
graphed before every media change and every two days, the media was replaced with fresh media containing 
either curcumin or DMSO.
ȀƪǤ Cells grown on coverslips were ixed with ice-cold 
methanol prior to blocking in 2% milk/TBST for 30 minutes and incubated with primary antibodies overnight 
at 4 °C. Antibody used was anti-rabbit JAK2 (3230S, cell Signalling, D2E12). Cells were washed and incubated 
with secondary antibody, anti-rabbit AF594 (A-11037, Invitrogen (1:250). Microscopy was carried out using a 
confocal microscope. Immunohistochemistry using a JAK2 antibody (3230S, Cell Signalling) was performed as 
previously described7. Quantiication of JAK2 staining intensity was performed using Fiji freeware. Image was 
irst colour-convoluted using the H -DAB function, image 2 (DAB) was converted to 8-bit and using the free-
hand selection tool, an area of interest was manually drawn around each tubule, mean grey intensity, maximum 
intensity (which is 255 for an 8-bit image) were obtained for each measured tubule. Data are presented as optical 
density (mean grey value) and were calculated following the formula Optical density = log(max intensity/mean 
intensity). To minimize the biases, which can be introduced in areas where there is no tissue (middle of a cyst), 
the non-cell compartment was excluded by drawing around the cysts.
Ǥ Cells were analysed by Western blotting with previously 
reported protocols43–46. In brief, cells were lysed using ice-cold Lysis Bufer (50 mM Tris (pH 7.4) 250 mM NaCl, 
0.3% Triton X-100, 1 mM EDTA) supplemented with protease inhibitor cocktail (Roche), freeze-thawed and 
sonicated. Whole cell lysates were boiled in 2xLaemmeli sample bufer for 5 minutes. Samples were resolved by 
SDS-PAGE and transferred using the Mini-PROTEAN system (Bio-Rad). Primary antibodies were anti-β-actin 
(ab8226, Abcam), anti-phosphorylated STAT3 (p-STAT3) (9145, Cell Signalling), anti-STAT3 (12640, Cell 
Signalling). Curcumin (08511-10MG, Sigma) was resuspended in DMSO and used at stated doses, DMSO served 
as vehicle control. For immunoblotting in cyst assays, Matrigel was irst dissolved using cultrex organoid har-
vesting solution, then cysts were lysed directly in 2xLaemmeli sample bufer and immunoblots carried out as 
described above.
Ǥ Pkd1nl/nl, harboring an intronic neomycin-selectable marker, or wild type littermate controls were 
used7,47. Pkd1nl/nl or control mice were sacriiced at 5 or 10 weeks of age and kidneys collected, formalin-ixed 
and parain embedded. 5-micron section were used for histological examination. All mouse experiments were 
done under the authority of a U.K. Home Oice license (license holder Dr Maria Fragiadaki, license number 
PPL7008968).
Ǥ Data were analysed using Prism GraphPad and Non-parametric, two-tailed, 
Mann-Whitney T-tests or one-way ANOVA were performed. Results with a P value of 0.05 or lower were consid-
ered statistically signiicant24.

All data including supporting datasets are made available as main igures or supplementary information iles.
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